Pilar Nozal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6693317/publications.pdf

Version: 2024-02-01

22	385	840776 11	752698 20
papers	citations	h-index	g-index

24	24	24	565
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterization of hypersensitivity reactions to polysulfone hemodialysis membranes. Annals of Allergy, Asthma and Immunology, 2022, , .	1.0	0
2	Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero. Journal of the American Academy of Dermatology, 2021, 84, 507-509.	1.2	7
3	Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Frontiers in Immunology, 2021, 12, 641656.	4.8	14
4	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. Scientific Reports, 2021, 11, 11632.	3.3	5
5	Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquerâ€“Simons syndrome). International Journal of Molecular Sciences, 2021, 22, 6608.	4.1	7
6	Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure. Seminars in Arthritis and Rheumatism, 2020, 50, E1-E2.	3.4	0
7	Immunological features of patients affected by Barraquer-Simons syndrome. Orphanet Journal of Rare Diseases, 2020, 15, 9.	2.7	11
8	Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Scientific Reports, 2020, 10, 17099.	3.3	1
9	Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 1913.	4.8	5
10	Evidence of ongoing complement activation on adipose tissue from an 11â€yearâ€old girl with Barraquerâ€“Simons syndrome. Journal of Dermatology, 2020, 47, 1439-1444.	1.2	6
11	Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Frontiers in Immunology, 2019, 10, 886.	4.8	52
12	The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clinical Rheumatology, 2019, 38, 949-954.	2.2	13
13	Complement as a diagnostic tool in immunopathology. Seminars in Cell and Developmental Biology, 2019, 85, 86-97.	5.0	33
14	Autoantibodies against alternative complement pathway proteins in renal pathologies. Nefrologia, 2016, 36, 489-495.	0.4	8
15	Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis. Journal of Clinical Immunology, 2016, 36, 517-527.	3.8	26
16	Autoanticuerpos frente a proteÃnas de la vÃa alternativa del complemento en enfermedad renal. Nefrologia, 2016, 36, 489-495.	0.4	8
17	Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Molecular Immunology, 2016, 70, 47-55.	2.2	33
18	Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation. BMC Nephrology, 2015, 16, 40.	1.8	18

#	Article	IF	Citations
19	Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunology Letters, 2014, 160, 163-171.	2.5	50
20	An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator. Molecular Immunology, 2014, 58, 194-200.	2.2	20
21	Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. CKJ: Clinical Kidney Journal, 2012, 5, 133-136.	2.9	20
22	Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion. Orphanet Journal of Rare Diseases, 2012, 7, 42.	2.7	48